1. Clinical & Scientific Overview
Saxagliptin & Alogliptin (TIP-MED-000062, Reference Code [4.18]) is classified under
Antidiabetic Medicines, Insulins & GLP-1 Agonists (Ch 04) as a Dipeptidyl Peptidase-4 (DPP-4) Inhibitors (Schedule H).
Within the Indian regulatory and compendial framework, it is governed under Schedule H & Schedule G Prescription Drug ('Caution: It is dangerous to take this preparation except under medical supervision' — Drugs Rules 1945).
Representative Indian Market Examples (Edition 2.7 Ch 04 [4.18], p. 53): Saxagliptin: Onglyza (AstraZeneca), Riax (Dr. Reddy's). Alogliptin: Nesina, Aloglipt — Strengths & Dosage Forms: Saxagliptin Tablets: 2.5 mg, 5 mg. Alogliptin Tablets: 6.25 mg, 12.5 mg, 25 mg
Saxagliptin Tablets: 2.5 mg, 5 mg. Alogliptin Tablets: 6.25 mg, 12.5 mg, 25 mg
3. Mechanism of Action & Pharmacodynamics
Dipeptidyl Peptidase-4 (DPP-4) Inhibitors (Schedule H) acting on target receptor/enzyme pathways in Antidiabetic Medicines, Insulins & GLP-1 Agonists (Ch 04): clinical efficacy is mediated via Dipeptidyl Peptidase-4 (DPP-4) Inhibitors (Schedule H) for Type 2 Diabetes Mellitus as adjunct to diet, exercise, and Metformin/SGLT2i (in patients without heart failure).
4. Therapeutic Indications & Evidence-Supported Uses
- Type 2 Diabetes Mellitus as adjunct to diet, exercise, and Metformin/SGLT2i (in patients without heart failure)
🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: Saxagliptin: 5 mg PO OD (Reduce to 2.5 mg OD if eGFR <45 mL/min or with strong CYP3A4 inhibitors). Alogliptin: 25 mg OD (12.5 mg OD if eGFR 30–59; 6.25 mg OD if eGFR <30)
Administration & Meal Timing: May be taken with or without food; swallow Saxagliptin tablets whole (do not split or cut film-coated tablets!) | Morning (Once Daily)
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Renal: Saxagliptin: 2.5 mg OD if eGFR <45 mL/min. Alogliptin: 12.5 mg OD (eGFR 30–59) or 6.25 mg OD (eGFR <30). Hepatic: Avoid in severe hepatic impairment
Renal: Saxagliptin: 2.5 mg OD if eGFR <45 mL/min. Alogliptin: 12.5 mg OD (eGFR 30–59) or 6.25 mg OD (eGFR <30). Hepatic: Avoid in severe hepatic impairment
Renal: Saxagliptin: 2.5 mg OD if eGFR <45 mL/min. Alogliptin: 12.5 mg OD (eGFR 30–59) or 6.25 mg OD (eGFR <30). Hepatic: Avoid in severe hepatic impairment
7. Contraindications, Precautions & High-Risk Warnings
- HEART FAILURE WARNING (SAVOR-TIMI 53): Saxagliptin increased hospitalisation for heart failure by 27% — AVOID Saxagliptin (and Alogliptin) in patients with established Heart Failure or moderate-to-severe CKD (prefer SGLT2i or Sitagliptin/Linagliptin!). Contraindicated in Type 1 DM, DKA, and prior pancreatitis
Key Clinical Precautions: Renal: Saxagliptin: 2.5 mg OD if eGFR <45 mL/min. Alogliptin: 12.5 mg OD (eGFR 30–59) or 6.25 mg OD (eGFR <30). Hepatic: Avoid in severe hepatic impairment
8. Adverse Effects Profile
- Upper respiratory tract infection, urinary tract infection, headache, peripheral oedema
- Hospitalisation for Heart Failure (dyspnoea, orthopnoea, rapid weight gain/ankle swelling), acute pancreatitis, severe arthralgia, bullous pemphigoid
- Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- Strong CYP3A4/5 inhibitors (Clarithromycin, Itraconazole, Ketoconazole) double Saxagliptin exposure -> reduce Saxagliptin to 2
- 5 mg OD! Additive hypoglycaemia with Sulfonylureas/Insulin
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.
Pharmacist Patient Counselling Points:
- Patient Counselling Checklist: Swallow tablet whole without cutting; report any shortness of breath when lying flat, sudden ankle swelling, or severe stomach pain immediately
- Meal & Clock Timing Instruction: May be taken with or without food; swallow Saxagliptin tablets whole (do not split or cut film-coated tablets!) (Morning (Once Daily))
- Missed Dose Protocol: Take same day if remembered; skip if next day
- Geriatric Dispensing Pearl: Avoid Saxagliptin in older adults with heart failure or reduced eGFR; prefer Linagliptin or Sitagliptin
Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Saxagliptin Tablets: 2.5 mg, 5 mg. Alogliptin Tablets: 6.25 mg, 12.5 mg, 25 mg
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) • Ch 04 [4.18] (p. 53)
Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: HANDBOOK_SOURCE_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.
13. Related Reference Monographs, Educational Guides & Visual Concept
💊 Related Pharmacological / Category Profiles
- [4.24]-C19 Intravenous Dextrose (25% / 50%) — Hyperglycaemic Glycogenolytic Hormone & Emergency Carbohydrate Re
- [4.24]-C20 Oral Glucose — Hyperglycaemic Glycogenolytic Hormone & Emergency Carbohydrate Re
- [4.1] Metformin Hydrochloride — Biguanide; Hepatic Gluconeogenesis Inhibitor & Insulin Sensitiser
- [4.2] Sitagliptin Phosphate — Dipeptidyl Peptidase-4 (DPP-4) Inhibitor (Gliptin); Incretin Enha
